Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34-selected progenitor cells
- Development stage
- Phase 2
- Lead developer
- Miltenyi Biotec
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34-selected progenitor cells refer to a cellular therapy product consisting of purified CD34+ hematopoietic stem and progenitor cells (PBPCs) derived from donor peripheral blood. Developed and studied at M.D. Anderson Cancer Center, this approach is utilized in allogeneic stem cell transplantation for patients with advanced hematological malignancies, including leukemia, lymphoma, and myelodysplastic syndrome. The manufacturing process involves ex vivo T-cell depletion through positive CD34+ selection, typically using the CliniMACS device, to deliver a 'megadose' of stem cells. This technique aims to facilitate donor-derived neutrophil and platelet engraftment while significantly reducing the incidence of acute and chronic graft-versus-host disease (GvHD) by removing the T-cells responsible for the immune attack on the recipient's tissues.
- Other names
- purified CD34+ peripheral blood progenitor cellsmegadose CD34 selected progenitor cellsCD34+ PBPC
Beyond the preview
Go deeper on CD34-selected progenitor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34-selected progenitor cells.